Pancreatic adenocarcinoma, version 2.2012: Featured updates to the NCCN guidelines

Margaret A. Tempero; J. Pablo Arnoletti; Stephen W. Behrman; Edgar Ben-Josef; Al B. Benson; Ephraim S. Casper; Steven J. Cohen; Brian Czito; Joshua D.I. Ellenhorn; William G. Hawkins; Joseph Herman; John P. Hoffman; Andrew Ko; Srinadh Komanduri; Albert Koong; Wen Wee Ma; Mokenge P. Malafa; Nipun B. Merchant; Sean J. Mulvihill; Peter Muscarella; Eric K. Nakakura; Jorge Obando; Martha B. Pitman; Aaron R. Sasson; Anitra Tally; Sarah P. Thayer; Samuel Whiting; Robert A. Wolff; Brian M. Wolpin; Deborah A. Freedman-Cass; Dorothy A. Shead

doi:10.6004/jnccn.2012.0073

Pancreatic adenocarcinoma, version 2.2012: Featured updates to the NCCN guidelines

Margaret A. Tempero, J. Pablo Arnoletti, Stephen W. Behrman, Edgar Ben-Josef, Al B. Benson, Ephraim S. Casper, Steven J. Cohen, Brian Czito, Joshua D.I. Ellenhorn, William G. Hawkins, Joseph Herman, John P. Hoffman, Andrew Ko, Srinadh Komanduri, Albert Koong, Wen Wee Ma, Mokenge P. Malafa, Nipun B. Merchant, Sean J. Mulvihill, Peter MuscarellaEric K. Nakakura, Jorge Obando, Martha B. Pitman, Aaron R. Sasson, Anitra Tally, Sarah P. Thayer, Samuel Whiting, Robert A. Wolff, Brian M. Wolpin, Deborah A. Freedman-Cass, Dorothy A. Shead

Research output: Contribution to journal › Review article › peer-review

258 Scopus citations

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma discuss the workup and management of tumors of the exocrine pancreas. These NCCN Guidelines Insights provide a summary and explanation of major changes to the 2012 NCCN Guidelines for Pancreatic Adenocarcinoma. The panel made 3 significant updates to the guidelines: 1) more detail was added regarding multiphase CT techniques for diagnosis and staging of pancreatic cancer, and pancreas protocol MRI was added as an emerging alternative to CT; 2) the use of a fluoropyrimidine plus oxaliplatin (e.g., 5-FU/leucovorin/oxaliplatin or capecitabine/oxaliplatin) was added as an acceptable chemotherapy combination for patients with advanced or metastatic disease and good performance status as a category 2B recommendation; and 3) the panel developed new recommendations concerning surgical technique and pathologic analysis and reporting.

Original language	English
Pages (from-to)	703-713
Number of pages	11
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	10
Issue number	6
DOIs	https://doi.org/10.6004/jnccn.2012.0073
State	Published - Jun 1 2012

Access to Document

10.6004/jnccn.2012.0073

Cite this

Tempero, M. A., Arnoletti, J. P., Behrman, S. W., Ben-Josef, E., Benson, A. B., Casper, E. S., Cohen, S. J., Czito, B., Ellenhorn, J. D. I., Hawkins, W. G., Herman, J., Hoffman, J. P., Ko, A., Komanduri, S., Koong, A., Ma, W. W., Malafa, M. P., Merchant, N. B., Mulvihill, S. J., ... Shead, D. A. (2012). Pancreatic adenocarcinoma, version 2.2012: Featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 10(6), 703-713. https://doi.org/10.6004/jnccn.2012.0073

@article{41c2b6c4e1464ba1b6edcbd00870e28a,

title = "Pancreatic adenocarcinoma, version 2.2012: Featured updates to the NCCN guidelines",

abstract = "The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma discuss the workup and management of tumors of the exocrine pancreas. These NCCN Guidelines Insights provide a summary and explanation of major changes to the 2012 NCCN Guidelines for Pancreatic Adenocarcinoma. The panel made 3 significant updates to the guidelines: 1) more detail was added regarding multiphase CT techniques for diagnosis and staging of pancreatic cancer, and pancreas protocol MRI was added as an emerging alternative to CT; 2) the use of a fluoropyrimidine plus oxaliplatin (e.g., 5-FU/leucovorin/oxaliplatin or capecitabine/oxaliplatin) was added as an acceptable chemotherapy combination for patients with advanced or metastatic disease and good performance status as a category 2B recommendation; and 3) the panel developed new recommendations concerning surgical technique and pathologic analysis and reporting.",

author = "Tempero, {Margaret A.} and Arnoletti, {J. Pablo} and Behrman, {Stephen W.} and Edgar Ben-Josef and Benson, {Al B.} and Casper, {Ephraim S.} and Cohen, {Steven J.} and Brian Czito and Ellenhorn, {Joshua D.I.} and Hawkins, {William G.} and Joseph Herman and Hoffman, {John P.} and Andrew Ko and Srinadh Komanduri and Albert Koong and Ma, {Wen Wee} and Malafa, {Mokenge P.} and Merchant, {Nipun B.} and Mulvihill, {Sean J.} and Peter Muscarella and Nakakura, {Eric K.} and Jorge Obando and Pitman, {Martha B.} and Sasson, {Aaron R.} and Anitra Tally and Thayer, {Sarah P.} and Samuel Whiting and Wolff, {Robert A.} and Wolpin, {Brian M.} and Freedman-Cass, {Deborah A.} and Shead, {Dorothy A.}",

year = "2012",

month = jun,

day = "1",

doi = "10.6004/jnccn.2012.0073",

language = "English",

volume = "10",

pages = "703--713",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

number = "6",

}

Tempero, MA, Arnoletti, JP, Behrman, SW, Ben-Josef, E, Benson, AB, Casper, ES, Cohen, SJ, Czito, B, Ellenhorn, JDI, Hawkins, WG, Herman, J, Hoffman, JP, Ko, A, Komanduri, S, Koong, A, Ma, WW, Malafa, MP, Merchant, NB, Mulvihill, SJ, Muscarella, P, Nakakura, EK, Obando, J, Pitman, MB, Sasson, AR, Tally, A, Thayer, SP, Whiting, S, Wolff, RA, Wolpin, BM, Freedman-Cass, DA & Shead, DA 2012, 'Pancreatic adenocarcinoma, version 2.2012: Featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 10, no. 6, pp. 703-713. https://doi.org/10.6004/jnccn.2012.0073

TY - JOUR

T1 - Pancreatic adenocarcinoma, version 2.2012

T2 - Featured updates to the NCCN guidelines

AU - Tempero, Margaret A.

AU - Arnoletti, J. Pablo

AU - Behrman, Stephen W.

AU - Ben-Josef, Edgar

AU - Benson, Al B.

AU - Casper, Ephraim S.

AU - Cohen, Steven J.

AU - Czito, Brian

AU - Ellenhorn, Joshua D.I.

AU - Hawkins, William G.

AU - Herman, Joseph

AU - Hoffman, John P.

AU - Ko, Andrew

AU - Komanduri, Srinadh

AU - Koong, Albert

AU - Ma, Wen Wee

AU - Malafa, Mokenge P.

AU - Merchant, Nipun B.

AU - Mulvihill, Sean J.

AU - Muscarella, Peter

AU - Nakakura, Eric K.

AU - Obando, Jorge

AU - Pitman, Martha B.

AU - Sasson, Aaron R.

AU - Tally, Anitra

AU - Thayer, Sarah P.

AU - Whiting, Samuel

AU - Wolff, Robert A.

AU - Wolpin, Brian M.

AU - Freedman-Cass, Deborah A.

AU - Shead, Dorothy A.

PY - 2012/6/1

Y1 - 2012/6/1

N2 - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma discuss the workup and management of tumors of the exocrine pancreas. These NCCN Guidelines Insights provide a summary and explanation of major changes to the 2012 NCCN Guidelines for Pancreatic Adenocarcinoma. The panel made 3 significant updates to the guidelines: 1) more detail was added regarding multiphase CT techniques for diagnosis and staging of pancreatic cancer, and pancreas protocol MRI was added as an emerging alternative to CT; 2) the use of a fluoropyrimidine plus oxaliplatin (e.g., 5-FU/leucovorin/oxaliplatin or capecitabine/oxaliplatin) was added as an acceptable chemotherapy combination for patients with advanced or metastatic disease and good performance status as a category 2B recommendation; and 3) the panel developed new recommendations concerning surgical technique and pathologic analysis and reporting.

AB - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma discuss the workup and management of tumors of the exocrine pancreas. These NCCN Guidelines Insights provide a summary and explanation of major changes to the 2012 NCCN Guidelines for Pancreatic Adenocarcinoma. The panel made 3 significant updates to the guidelines: 1) more detail was added regarding multiphase CT techniques for diagnosis and staging of pancreatic cancer, and pancreas protocol MRI was added as an emerging alternative to CT; 2) the use of a fluoropyrimidine plus oxaliplatin (e.g., 5-FU/leucovorin/oxaliplatin or capecitabine/oxaliplatin) was added as an acceptable chemotherapy combination for patients with advanced or metastatic disease and good performance status as a category 2B recommendation; and 3) the panel developed new recommendations concerning surgical technique and pathologic analysis and reporting.

UR - http://www.scopus.com/inward/record.url?scp=84863206071&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2012.0073

DO - 10.6004/jnccn.2012.0073

M3 - Review article

C2 - 22679115

AN - SCOPUS:84863206071

SN - 1540-1405

VL - 10

SP - 703

EP - 713

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 6

ER -

Pancreatic adenocarcinoma, version 2.2012: Featured updates to the NCCN guidelines

Abstract

Access to Document

Other files and links

Fingerprint

Cite this